335 related articles for article (PubMed ID: 33162976)
1. Pretreatment Peripheral B Cells Are Associated With Tumor Response to Anti-PD-1-Based Immunotherapy.
Yuan S; Liu Y; Till B; Song Y; Wang Z
Front Immunol; 2020; 11():563653. PubMed ID: 33162976
[TBL] [Abstract][Full Text] [Related]
2. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang Q; Xie B; Liu S; Shi Y; Tao Y; Xiao D; Wang W
Front Immunol; 2021; 12():773168. PubMed ID: 35003090
[TBL] [Abstract][Full Text] [Related]
3. The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy.
Wang X; Wang F; Zhong M; Yarden Y; Fu L
Mol Cancer; 2020 May; 19(1):81. PubMed ID: 32359357
[TBL] [Abstract][Full Text] [Related]
4. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
5. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
6. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract][Full Text] [Related]
7. Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy.
Hu W
Thorac Cancer; 2020 Jan; 11(1):3-5. PubMed ID: 31722117
[No Abstract] [Full Text] [Related]
8. Value of
Kaira K; Kuji I; Kagamu H
Cancer Imaging; 2021 Jan; 21(1):11. PubMed ID: 33441183
[TBL] [Abstract][Full Text] [Related]
9. Current issues and perspectives in PD-1 blockade cancer immunotherapy.
Chamoto K; Hatae R; Honjo T
Int J Clin Oncol; 2020 May; 25(5):790-800. PubMed ID: 31900651
[TBL] [Abstract][Full Text] [Related]
10. T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker.
Akyüz N; Brandt A; Stein A; Schliffke S; Mährle T; Quidde J; Goekkurt E; Loges S; Haalck T; Ford CT; Asemissen AM; Thiele B; Radloff J; Thenhausen T; Krohn-Grimberghe A; Bokemeyer C; Binder M
Int J Cancer; 2017 Jun; 140(11):2535-2544. PubMed ID: 27925177
[TBL] [Abstract][Full Text] [Related]
11. Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination.
De Guillebon E; Dardenne A; Saldmann A; Séguier S; Tran T; Paolini L; Lebbe C; Tartour E
Int J Cancer; 2020 Sep; 147(6):1509-1518. PubMed ID: 31997345
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
Front Immunol; 2020; 11():372. PubMed ID: 32210968
[TBL] [Abstract][Full Text] [Related]
13. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
Ren D; Hua Y; Yu B; Ye X; He Z; Li C; Wang J; Mo Y; Wei X; Chen Y; Zhou Y; Liao Q; Wang H; Xiang B; Zhou M; Li X; Li G; Li Y; Zeng Z; Xiong W
Mol Cancer; 2020 Jan; 19(1):19. PubMed ID: 32000802
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
15. Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors.
Del Re M; van Schaik RHN; Fogli S; Mathijssen RHJ; Cucchiara F; Capuano A; Scavone C; Jenster GW; Danesi R
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188463. PubMed ID: 33137405
[TBL] [Abstract][Full Text] [Related]
16. Dynamic changes in circulating PD-1
Kim CG; Hong MH; Kim KH; Seo IH; Ahn BC; Pyo KH; Synn CB; Yoon HI; Shim HS; Lee YI; Choi SJ; Lee YJ; Kim EJ; Kim Y; Kwak JE; Jung J; Park SH; Paik S; Shin EC; Kim HR
Eur J Cancer; 2021 Jan; 143():113-126. PubMed ID: 33302114
[TBL] [Abstract][Full Text] [Related]
17. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
[TBL] [Abstract][Full Text] [Related]
18. Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer.
Hurkmans DP; Verdegaal EME; Hogan SA; de Wijn R; Hovestad L; van den Heuvel DMA; Ruijtenbeek R; Welters MJP; van Brakel M; Basak EA; Pinedo HM; Lamers CHJ; van de Werken HJG; Groten JP; Debets R; Levesque MP; Dummer R; Kapiteijn E; Mathijssen RHJ; Aerts JGJV; van der Burg SH
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33427690
[TBL] [Abstract][Full Text] [Related]
19. Immune metabolism in PD-1 blockade-based cancer immunotherapy.
Kumar A; Chamoto K
Int Immunol; 2021 Jan; 33(1):17-26. PubMed ID: 32622347
[TBL] [Abstract][Full Text] [Related]
20. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]